Merck (MRK) Up 17% YTD on Keytruda Strength: Should You Buy?

Merck’s (MRK) stock has risen 17.5% so far this year, underperforming an increase of 24.2% for the industry, as seen in the chart below. Merck Stock Underperforms Industry Image Source: Zacks Investment ResearchMerck boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda approved for several types of cancer and alone accounting for more than 45% of the company’s pharmaceutical sales. The drug has played an instrumental role in driving Merck’s steady revenue growth in the past ...